MERCK Serono has informed the
TGA of a decision to withdraw its
Movectro (cladribine) multiple
sclerosis treatment from supply.
The company says that additional
clinical trials would be needed to
meet US FDA and European
Medicines Agency requirements for
the approval of the drug, and has
decided not to pursue further the
worlwide approval process due to
the length of time required and the
“changing competitive landscape”.
Movectro is currently only
supplied in Australia through a
select number of neurologists, with
about 150 patients receiving the
medication.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.